| Symbol | Name | Last Close | Mkt Cap | DailyStocks' Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
|
Vote Now! Tuesday’s Close |
|---|---|---|---|---|---|
| SNY | Sanofi | $43.75 | $109.14B | N/A |
Emergent Begins Phase III Study on Anthrax Vaccine AV7909
http://www.zacks.com/stock/news/362304/emergent-begins-phase-iii-study-on-anthrax-vaccine-av7909?cid=CS-ZC-FT-362304
Mar 20, 2019 - Emergent (EBS) kicks off a late-stage study on its investigational anthrax vaccine AV7909.
0
Regeneron, Sanofi Get EC Nod for Label Expansion of Praluent
http://www.zacks.com/stock/news/360917/regeneron-sanofi-get-ec-nod-for-label-expansion-of-praluent?cid=CS-ZC-FT-360917
Mar 18, 2019 - Regeneron (REGN) and partner Sanofi receives approval in Europe for the label expansion of Praluent to reduce cardiovascular (CV) risk in adults with established atherosclerotic CV disease.
0
Biotech Stock Roundup: REGN Gets FDA Nod for Dupixent & Other Pipeline News
http://www.zacks.com/stock/news/359263/biotech-stock-roundup-regn-gets-fda-nod-for-dupixent-other-pipeline-news?cid=CS-ZC-FT-359263
Mar 13, 2019 - Key highlights of the past week are regulatory and pipeline developments.
0
Should Value Investors Consider Sanofi (SNY) Stock Now?
http://www.zacks.com/stock/news/359203/should-value-investors-consider-sanofi-sny-stock-now?cid=CS-ZC-FT-359203
Mar 13, 2019 - Let's see if Sanofi (SNY) stock is a good choice for value-oriented investors right now from multiple angles.
0
Regeneron/Sanofi's Dupixent Gets FDA Nod for Label Expansion
http://www.zacks.com/stock/news/359028/regeneron-sanofis-dupixent-gets-fda-nod-for-label-expansion?cid=CS-ZC-FT-359028
Mar 12, 2019 - The FDA approves a label expansion of Regeneron's (REGN) asthma drug, Dupixent for moderate-to-severe atopic dermatitis in adolescents.
0
Sanofi's Dupixent Gets FDA Priority Status for Nasal Polyps
http://www.zacks.com/stock/news/358687/sanofis-dupixent-gets-fda-priority-status-for-nasal-polyps?cid=CS-ZC-FT-358687
Mar 11, 2019 - Sanofi (SNY) and partner Regeneron's (REGN) Dupixent gets FDA's priority review status for inadequately controlled severe chronic rhinosinusitis with nasal polyps.
0
SNY ending 'Daily News Live' after 13-year run and will launch a new show hosted by Justine Ward
http://www.nydailynews.com/sports/ny-sports-sny-dailynewslive-raissman-20190307-story.html
Mar 07, 2019 -
After 13 years of unpredictable sportswriters and assorted Gasbags delivering the word and their insights on the fly every afternoon at 5 p.m., SportsNet New York is cancelling "Daily News Live" and replacing it with "The Thread" a fast-paced show covering the hottest sports news of the day.
The...
7
Roche's (RHHBY) sNDA for Flu Candidate Accepted by the FDA
http://www.zacks.com/stock/news/357971/roches-rhhby-snda-for-flu-candidate-accepted-by-the-fda?cid=CS-ZC-FT-357971
Mar 06, 2019 - The FDA accepts Roche's (RHHBY) sNDA for Xofluza to treat influenza in people at high risk of complications.
0
Top Stock Reports for Salesforce, Booking Holdings & VMware
http://www.zacks.com/research-daily/218411/top-stock-reports-for-salesforce-booking-holdings-vmware?cid=CS-ZC-FT-218411
Mar 06, 2019 - Top Stock Reports for Salesforce, Booking Holdings & VMware
0
3 Big Pharmas Trying to Pop the Rebate Bubble
https://www.fool.com/investing/2019/03/06/3-big-pharmas-trying-to-pop-the-rebate-bubble.aspx?source=iedfolrf0000001
Mar 06, 2019 - Pharmaceutical companies are suddenly eager to lower drug prices.
0